Form 4/A for VRCA Verrica Pharmaceuticals Inc.
Accepted 2025-02-06 00:00:00 ET · period of report 2023-08-24 · accession 0001415889-25-003230 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| A | 2025-02-06 | 2023-08-24 | VRCA | Bonaccorso Joe | Chief COMMERCIAL Off | A - Grant | $0.00 | +125.0K | 187.7K | +199% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-08-24 | A | A | 125,000 | $0.00 | 187,738 | D | — | — | (F1) Represents restricted stock unit ("RSU") awards with performance based vesting, which were originally granted in March 2023. The RSUs vested 50% upon the first commercial sale of VP-102 on August 24, 2023, and the remaining 50% vested on August 24, 2024, the one year anniversary of the first sale. (F2) The number of RSUs awarded in the initial Form 4 was unintentionally misreported, as only the number of shares that vested on August 24, 2023 were reported as opposed to the full size of the award. This amendment corrects the number RSUs awarded and the number of securities beneficially owned after the reported transaction. |